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Abstract
Background: Electronic prescribing is increasingly being used in primary care and in hospitals. Studies on the effects 
of e-prescribing systems have found evidence for both benefit and harm. The aim of this study was to identify features 
of e-prescribing software systems that support patient safety and quality of care and that are useful to the clinician and 
the patient, with a focus on improving the quality use of medicines.
Methods: Software features were identified by a literature review, key informants and an expert group. A modified 
Delphi process was used with a 12-member multidisciplinary expert group to reach consensus on the expected 
impact of the features in four domains: patient safety, quality of care, usefulness to the clinician and usefulness to the 
patient. The setting was electronic prescribing in general practice in Australia.
Results: A list of 114 software features was developed. Most of the features relate to the recording and use of patient 
data, the medication selection process, prescribing decision support, monitoring drug therapy and clinical reports. The 
expert group rated 78 of the features (68%) as likely to have a high positive impact in at least one domain, 36 features 
(32%) as medium impact, and none as low or negative impact. Twenty seven features were rated as high positive 
impact across 3 or 4 domains including patient safety and quality of care. Ten features were considered "aspirational" 
because of a lack of agreed standards and/or suitable knowledge bases.
Conclusions: This study defines features of e-prescribing software systems that are expected to support safety and 
quality, especially in relation to prescribing and use of medicines in general practice. The features could be used to 
develop software standards, and could be adapted if necessary for use in other settings and countries.
Background
Medicine prescribing and health information record-
keeping are changing from paper-based to computerised
processes in healthcare systems all over the world. Elec-
tronic prescribing (e-prescribing) can be a stand alone
process, but is usually part of an electronic health record
system which may also link to pathology, radiology and
patient administration systems. In the UK, Australia and
some European countries the majority of prescribing in
primary care is computerised, whereas uptake is less
extensive in hospitals. In the United States, e-prescribing
is widely used in some hospital-based organisations but is
less common in primary care; this is likely to change with
recent government incentives to encourage e-prescrib-
ing[1].
Most studies on the effects of e-prescribing systems
have been carried out in the hospital setting, and have
found evidence for both benefit and harm. E-prescribing
produces legible prescriptions, can provide rapid access
to information and decision support, and can reduce pre-
scribing errors and adverse drug events [2-4]. It has also
b e e n  a s s o c i a t e d  w i t h  n e w  t y p e s  o f  e r r o r s  a n d  a d v e r s e
patient outcomes [5-7]. The effects of e-prescribing on
the quality of prescribing depend on a range of factors
that include the healthcare setting, user training and
behaviour, availability of appropriate hardware and tech-
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nical support, the computer system used including the
availability and quality of decision support, and integra-
tion of the system into work practices[8,9].
Numerous software applications have been developed
for e-prescribing in the last 10 to 15 years, however guid-
ance and standards for these systems has lagged behind
development of the applications. The question of how
these systems can maximise benefits and limit harm is
receiving increasing attention. Some research has been
done on the desirable functionality of these systems, [10-
12] and on safety features[13,14]. Accreditation and certi-
fication programs such as the General Practice Systems of
Choice program in the UK[15] and the Certification
Commission for Health Information Technology in the
United States[16] have been introduced. In Australia gen-
eral practice prescribing systems have been used since
the early 1990s, and in 2005 almost 90% of Australian
general practitioners (GPs) were prescribing electroni-
cally[17]. The prescribing systems available have been
developed without standards or accreditation and they
have markedly different user interfaces and capabilities.
We undertook a study to identify features of prescrib-
ing systems used in general practice that support patient
safety and quality of care and that are useful to the clini-
cian and the patient, based on the consensus of an expert
group. The focus was on the quality use of medicines
(QUM i.e. judicious, effective and safe use of medicines):
this is one of the four key objectives of the Australian
National Medicines Policy, and the National Prescribing
Service is the organisation that is responsible for promot-
ing QUM. A list of the 114 features identified, together
with their expected impact in four domains, is reported
in this paper.
Methods
A list of features was developed by the authors and an
expert panel was convened to establish consensus on the
expected impact of these features. Features included
functional capabilities and other attributes of the pre-
scribing system.
The study was conducted between November 2006 and
December 2007 and was overseen by an 8-member study
guidance group. The study protocol was approved by the
Australian Department of Health and Ageing Ethics
Committee.
Identification of features
The features were identified by a literature review , key
informant interviews and invited written submissions.
Literature review
Key papers and reports were identified by members of
the project team who were familiar with work in this area.
We searched Ovid MEDLINE(R) (Jan 1995 - Feb 2007)
and used Google to search the internet to identify papers
that covered features of e-prescribing systems that could
significantly improve safety or quality, especially in rela-
tion to prescribing medicines and monitoring drug ther-
apy. Scientific journals and grey literature were included.
The papers and reports were assessed for relevance, and
information about potential features was extracted.
Key informant interviews
We sought the opinions of Australian experts in general
practice, public health, quality and safety, health infor-
matics and pharmacy. A telephone interview guide was
developed asking participants to identify current or
potential features of electronic prescribing systems that
could contribute to patient safety and quality patient care,
or would be useful to the clinician or the patient. The
interview guide was pilot tested with a user and non-user
of e-prescribing systems, and was incorporated into a
template to facilitate computer data entry during the
interviews.
Written submissions
Written submissions were invited from members of the
Medical Software Industry Association, the body repre-
senting general practice software vendors for most sys-
tems in use in Australia.
Development of features list
A list of candidate features was developed and was
reviewed by five members of the project team (MW, MS,
JR, KH, AS) in a series of round-table discussions. The
inclusion of each feature was considered in terms of evi-
dence or expectation that it would contribute to
improved safety and quality or would be useful to clini-
cians or patients, and relevance to the general practice
setting in Australia. For those features selected, some
were merged, separated or the wording adapted for local
relevance while maintaining the key concepts. The final
wording of each feature was reviewed to ensure that it
was clear, concise and accurate. The ability to implement
each feature was considered - that is, whether it was pos-
sible to implement the feature given constraints such as
lack of a suitable agreed standard or knowledge base. A
rationale for each feature was developed based on the lit-
erature review and the clinical experience of the research-
ers, and the features were classified into convenient
groups.
Confirmation of features and rating of expected impact
A modified Delphi process was used with a 12-member
multidisciplinary group of experts to gain consensus on
the expected impact of the features. The Delphi process is
used to predict effects where the available evidence is
limited[18]. We used a modified process including face to
face meetings because the project was complex and there
were a large number of items to be scored. Similar tech-Sweidan et al. BMC Medical Informatics and Decision Making 2010, 10:21
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niques have been used in other studies to gain consensus
on important features of information systems and quality
of care indicators[19,20].
Expert panel recruitment
Participants were selected based on their experience in
general practice, public health, quality and safety, health
informatics, pharmacy or consumer health issues. Prior
to the first meeting, each participant received informa-
tion about the study and signed consent, confidentiality
and declaration of interests forms. Participants were
compensated for their time and travel expenses according
to the organisation's remuneration policy.
Expert panel role
The panel members were asked to: (1) confirm that the
proposed features were relevant, and add any other fea-
tures that they considered important; (2) rate the
expected impact of each feature (using a -5 to + 5 scale)
across four domains, via a modified Delphi process (see
Figures 1 and 2) and (3) define the cut off levels for cate-
gorising the features as being of high positive, medium
positive or low/negative impact. The panel members
were required to attend two meetings and complete three
rounds of ratings over a two month period. The purpose
of the first face to face meeting was to ensure that expert
panel members understood the background to the proj-
ect, the aims of the Delphi process and the scoring sys-
tem. The purpose of the second meeting was to reach
consensus on those items where agreement had not been
reached in the third round of individual ratings.
Results
Identification of features
A list of 114 features was developed, selected from an ini-
tial list of over 200 candidate features; these were based
on the review of the literature, key informant interviews
and expert panel member recommendations.
Literature review
Six key literature sources[10-12,21-23] were used to
inform the development of 102/114 (89%) of the features,
with most of the features supported by more than one
source. Of the six key sources, three of the studies or
reports were related to prescribing in primary care or
outpatient clinics, although they had different purposes.
The first was a study to identify features which would
reduce prescribing hazards,[10] the second identified fea-
tures to improve patients' health outcomes and their abil-
ity to manage costs[11] and the third was intended to
assist GPs in purchasing prescribing software sys-
tems[21]. The NHS ePrescribing Functional Specification
for NHS Trusts[12] outlines e-prescribing specifications
that are mostly applicable to the acute care setting
although some are also relevant in primary care. The
other two reports were published by international organi-
sations and describe functionality or standards for elec-
tronic health record systems including prescribing. The
Health Level 7 Electronic Health Record Functional
Model[22] covers a "superset" of functions of an elec-
tronic health record system, intended to be adapted to
different settings. The International Standards Organisa-
tion standard Health informatics - Requirements for an
electronic health record architecture outlines clinical and
technical requirements[23]. Eleven other references were
also useful in the identification of relevant fea-
tures[6,17,24-32].
Key informant interviews
Twenty-seven experts were contacted, 19 of these agreed
to participate and 17 completed the interview. Their pro-
fessional backgrounds were in general practice (6), health
informatics or information technology (4), pharmacy (3),
a medical specialty (2), nursing (1) or health policy (1),
with many also having expertise in healthcare quality and
safety. The key informants identified a broad range of fea-
tures, with 62 of the features based on or supported by
key informant comments.
Feedback from software vendors
General comments were received, most of them about
the project methods and the need for industry standards
in order to improve systems. These were not incorpo-
rated into the features list.
Preliminary features list
One hundred and seven features were selected for inclu-
sion initially, with 7 added later by the expert panel (see
below). The features were classified into eight groups:
patient data (18 features), medication selection (24), deci-
sion support (22), patient information and education (6),
monitoring, reports and recalls (17), interoperability and
communication (13), security and administration (9) and
transparency (5).
Confirmation of features and rating of expected impact
Expert panel members
The 12-member expert panel was assembled from an ini-
tial pool of 23 potential participants, all based in Austra-
lia; their details are shown in Figure 3 and the
Acknowledgments. Those who were not selected were
either not available (7) or declined to participate (4). All
12 members completed the entire ratings process. The
face to face meetings were attended by at least 75% of the
panel members, with input via teleconference or email for
those members unable to attend in person.
Expert panel ratings and recommendations
The expert panel recommended that all 107 features on
the preliminary list be retained, and suggested the addi-
tion of seven new features, making a total of 114 features.
Panel members rated the expected impact of each feature
across four domains: patient safety, quality of care, use-
fulness to the clinician and usefulness to the patient (see
Figure 2). At the end of round 1 there was agreementSweidan et al. BMC Medical Informatics and Decision Making 2010, 10:21
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Figure 1 Modified Delphi process.
Face to face meeting 1 
 Background information and discussion to familiarise expert panel members with project 
and features.  
 Panel members asked to rate a subset of the features in order to demonstrate the rating 
process and to clarify any uncertainties.  
 Distribution of ratings form for round 1. 
 
Round 1 rating 
 Panel members rated all features across 4 domains and provided comments; returned 
results to the researchers by post.  
 Results from round 1 aggregated and sent to panel members by email: documents included 
median scores, interquartile range (IQR), de-identified individual scores and comments 
from all panel members.  
 
Round 2 rating 
 Panel members given opportunity to re-rate features and provide comments based on 
round 1 feedback; returned results to the researchers by post.  
 Results from round 2 aggregated and sent to panel members by email (as for round 1). 
 
Round 3 rating  (including face to face meeting 2) 
 Panel members given opportunity to re-rate features based on round 2 feedback, and asked 
to bring their final ratings to the second face to face meeting.   
 At the meeting, panel members discussed median scores from round 2 and any changes to 
individual ratings, focussing on those items where disagreement between panel members 
remained. 
 Consensus reached on median scores for all features. Sweidan et al. BMC Medical Informatics and Decision Making 2010, 10:21
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among panel members (defined in Figure 2) for 55% of
the items rated. Feedback on results from round 1
(median scores, interquartile range (IQR), de-identified
individual scores and comments) was provided to panel
members prior to round 2 and members were asked to
confirm their ratings or to re-rate their original scores in
light of the feedback. In round 2 there was agreement for
78% of the items rated. In round 3, consensus was
reached on the median scores for all 114 features in each
of the four domains.
The panel recommended cut off points for classifying
the expected level of impact of each feature as follows:
high positive impact = at least 1 of the 4 median scores is
4-5; medium positive impact = at least 1 of the 4 median
scores is 2-3.5 (and none are ≥ 4); low positive or negative
impact = all four median scores are <2.
Final features and their expected impact
The complete features list including the expected impact
in each of the four domains is shown in Additional file 1.
Most of the features relate to the recording and use of
patient data, the medication selection process, prescrib-
ing decision support, monitoring drug therapy or clinical
reporting. Other areas are resources for patients, interop-
erability, security and transparency. Seventy eight fea-
tures (68%) were classified as likely to have a high positive
Figure 2 Ratings system used by expert panel.
The expected positive or negative impact of each feature was rated across four domains:  
1.  Patient safety: Is the inclusion of the feature in software likely to improve, worsen or have no 
effect on patient safety? 
2.  Quality of care: Is the inclusion of the feature in software likely to support, detract from or 
have no effect on the provision of good quality clinical care? 
3.  Useful to the clinician: Is the inclusion of the feature in software likely to enhance, disrupt or 
have no effect on clinician work practices? 
4.  Useful to the patient: Is the inclusion of the feature in software likely to be useful to the 
patient, impact adversely on the patient, or have no direct impact on the patient. Examples 
include improving the communication between prescribers and consumers, assisting consumer 
decision-making about their management, or meeting expectations about the way their health 
information is used. 
An 11-point rating scale was used, similar to the 15-point scale used by Bell et al.[11] The scale 
ranged from -5 (largest negative impact) to +5 (largest positive impact), with -4 to -5 being for 
effects that were “clearly negative” and +4 to +5 for effects that were “clearly positive”. Scores of 
-1 to -3 and +1 to +3 indicated some negative or positive effect, and a zero value indicated no 
effect. It was also possible to choose “don’t know” if the person felt that they had insufficient 
knowledge or experience to rate that feature. It was to be assumed that the feature had been 
implemented properly in the software and worked well. 
The median score and the interquartile range (IQR) were calculated for each of the four domains 
for each feature. “Agreement” between panel members was defined as an item with scores where 
the IQR was ≤ 2 and there were no outliers (defined as those scores that were more than 1.5 x IQR 
from the 25th or 75th percentile) or the range of all 12 scores was ≤ 2. “Disagreement” included 
all items not meeting the criteria for “agreement” ie. those where  the IQR was >2 or there were 
outliers (scores > 1.5 x IQR from the 25th or 75th percentile).  Sweidan et al. BMC Medical Informatics and Decision Making 2010, 10:21
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impact in at least one domain, 36 features (32%) as
medium impact, and none as low or negative impact.
Twenty seven features (24%) were rated as high impact
across three or four domains including safety and quality;
these are highlighted in Additional file 1 and are
described in the following two paragraphs. Ten features
were considered "aspirational", that is they could not be
implemented at the time of the study, either because of a
Figure 3 Expert panel members. *1 = clinical, 2 = academic, 3 = health policy, 4 = quality and safety, 5 = health informatics, 6 = consumer.
Participant  Gender  Professional background  Role or area of 
expertise* 
1 F  General  practitioner  1,2 
2 F  General  practitioner  1,3,4 
3 M  General  practitioner  1,3,4 
4 M  General  practitioner  1,3,4 
5 M  General  practitioner  1,5 
6  M  Hospital medical specialist  1,3,5 
7  M  Clinician, health informatician  5 
8  M  Clinician, health informatician  5 
9  F  Health informatics researcher  2,5 
10 M  Pharmacist  -  hospital  1,2 
11 M  Pharmacist  -  community  1,2 
12 F  Consumer  6 Sweidan et al. BMC Medical Informatics and Decision Making 2010, 10:21
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lack of agreed standards or lack of nationally accepted
knowledge bases being available in a suitable format.
The 27 features of e-prescribing systems that were con-
sidered likely to have high positive impact across multiple
domains (including quality and safety) include the follow-
ing: The system should allow the user to record patient
clinical details, medication information, allergies and
pregnancy and breastfeeding status; this information
should be recorded in a format that can be used for deci-
sion support, and should be displayed to the user. When
there are changes to or discontinuation of medications,
the system should allow the date, prescriber and reason/s
for change or discontinuation to be recorded. Apart from
direct entry of data into the patient record, it should be
possible to import clinical data from external sources and
also to export it to external sources, allowing details of
the record to be shared and updated. As part of the medi-
cation selection process, the system should offer the user
information on recommended therapeutic options for the
condition being treated, and provide access to evidence-
based drug information at the time of prescribing. The
system should display medication lists in a way that
makes it easy for the user to differentiate between simi-
larly named products, to reduce the risk of product selec-
tion errors. The system should also provide information
on drug strength, form and dosage, and display the
generic name when a product is selected by brand name.
All decision support should be underpinned by high
quality, up to date knowledge bases and guidelines, and
alerts should be prioritised by clinical importance. Warn-
ings should be provided when prescribing a drug if: that
drug (or another drug in the same class) is already on the
current medications list; the patient has a recorded con-
traindication to the drug, including allergy, pregnancy or
breastfeeding; the drug is renally cleared and the patient
has renal impairment; the dosage regimen may be harm-
ful; or where the regulator has issued a safety warning for
a product. Finally, the system should enable the user to
produce a suitably formatted current medication list for
the patient, and should use standard clinical terminolo-
gies and messaging protocols.
Discussion
One hundred and fourteen features of general practice
prescribing systems that support quality and safety were
defined, with a focus on promoting better use of medi-
c i n e s .  A l l  f e a t u r e s  w e r e  r a t e d  b y  a  m u l t i d i s c i p l i n a r y
expert panel as being likely to have medium to high posi-
tive impact on safety, quality of care and/or usefulness to
the clinician or the patient. Ten "aspirational" features
were identified; they require significant system changes
before they can be implemented, for example availability
and use of national clinical terminologies and unique
patient identifiers. Many of these are essential "building
blocks" for e-health, and are necessary for sharing patient
data, for example a shared medication list.
The strengths of our study include the comprehensive
approach and the focus on safety and quality, particularly
in relation to medicines use. The features were developed
and rated drawing on multiple sources, including the
international literature and experts with different back-
grounds. An expert panel reached consensus on the
expected impact of the features not only on patient safety
and quality of care, but also on whether they were likely
to be useful to clinicians and to patients.
The scope of our features list has some limitations. The
features were developed for the Australian general prac-
tice setting, although we believe most of the features are
relevant to e-prescribing in other settings. Non-clinical
functions of software were largely excluded, for example
billing and practice management. The features are high
level statements rather than detailed specifications; if
they are used as the basis for specifications, factors such
as usability and the quality of knowledge bases used for
decision support also need to be considered.
Our results endorse the importance of many of the fea-
tures that others have identified in different settings as
being important for safety and quality in e-prescribing.
We took a similar approach to Avery et al.[10] in the UK
and Bell et al.[11] in the United States, with a common
goal in all three studies being to support patient safety.
Our study focussed on the quality use of medicines in
general practice in Australia; however, our list of 114 fea-
tures includes related aspects of prescribing systems that
we believe are important, for example security and back-
up of clinical data, transparency and support for privacy
legislation. Avery et al.[10] produced 55 clinical state-
ments related to medicines management errors and
safety considerations for general practice computer sys-
tems in the UK, and their importance was rated. Bell et
al.[11] developed 60 recommendations for e-prescribing
systems' ability to meet the goals of improving patient
safety and health outcomes, helping patients manage
costs, maintaining patient privacy and promoting clini-
cians' acceptance of electronic prescribing. The recom-
mendations were rated by level of impact on each of these
four dimensions.
While the rating of our features cannot be compared
directly with those of Avery et al.[10] and Bell al[11] (as
different scales were used), there was considerable over-
lap in the areas rated as important. In Avery et al's study
the key themes around which consensus was reached on
importance included computerised alerts; the need to
minimise spurious alerts; making it difficult to override
critically important alerts; having audit trails of such
overrides; effective computer-user interface; and the need
to be able to run safety reports[10]. For the 60 recom-
m e n d a t i o n s  m a d e  b y  B e l l  e t  a l ,  5 2  w e r e  r a t e d  i n  t h eSweidan et al. BMC Medical Informatics and Decision Making 2010, 10:21
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clearly positive range on the 'patient safety and health
outcomes' dimension, including all 19 features related to
patient identification, medication selection and alerts and
warnings for prescribing[11].
The features list produced in this study could be used
by policymakers and professional bodies to develop certi-
fication criteria or standards for prescribing software sys-
tems, and as guidance for software vendors. It could also
be used by clinicians to assist them in assessing the suit-
ability of an e-prescribing system when selecting or
changing systems.
Several lines of follow on work suggest themselves.
Detailed specifications or criteria can be developed for
incorporating (or testing) the features in e-prescribing
systems. (Following this study we assessed seven e-pre-
scribing systems in Australia to find out whether the fea-
tures had been implemented in these systems; the results
will be reported in the near future). It would be valuable
to observe the actual impact of each feature when imple-
mented. We would emphasise the importance of moni-
toring and evaluating the effects of e-prescribing systems
when they are introduced or changed, being especially
vigilant for unintended effects. Finally, new functionality
will become possible as technologies and systems evolve;
any list of recommended software features requires ongo-
ing review.
Conclusions
This study defines the features of e-prescribing systems
that are expected to support safety and quality, with a
focus on prescribing and use of medicines in general
practice. The definition of such features is important for
the development of software standards, with the aim
being to maximise the benefits and minimise potential
harms associated with e-prescribing. Software standards
and certification processes are required to ensure that the
features are incorporated into e-prescribing systems. The
features list could be adapted for use in other settings and
countries.
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